Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1Diana Cortés‐Selva, Raluca Verona, Elena Ramos et al.|Blood|2022Cited by 46
Biomarker Correlates of Response to Ciltacabtagene Autoleucel in Patients with Relapsed or Refractory Multiple Myeloma from CARTITUDE-1, a Phase 1b/2 Open-Label Study, at the ~3 Year Follow-upRocío Montes de, Enrique Zudaire, Junchen Gu et al.|Blood|2023Cited by 9
Longitudinal mechanisms of response, resistance and relapse to teclistamab in multiple myeloma: results from MajesTEC-1Deeksha Vishwamitra, Raluca Verona, Sheri Skerget et al.|Haematologica|2026Cited by 0